ML20217Q292

From kanterella
Jump to navigation Jump to search
Discusses 881209 Petition Submitted by Theragenics Corp Requesting Amend to 10CFR35.400 to Add Pd-103 as Sealed Source in Seeds for Interstitial Treatment of Cancer.Final Amend Published on 891012 in Fr
ML20217Q292
Person / Time
Issue date: 11/03/1989
From: Bahadur S
NRC OFFICE OF NUCLEAR REGULATORY RESEARCH (RES)
To: Cooper H
AFFILIATION NOT ASSIGNED
Shared Package
ML20217P754 List:
References
FOIA-98-86 NUDOCS 9804100377
Download: ML20217Q292 (2)


Text

p-

~).

ga ato MN vy'o UNITED STATES g

8' NUCLEAR REGULATORY COMMISSION n

'y WASHINGTON, D. C. 20555 e,

e

'4

,O',

(

9 i

Nov o s 1989

)

bl

/

Mr/HowardT. Cooper Ibigulatory and Medical Affairs Director i

%eragenics Corporation 440TenthStreet,N.W.,SuiteN?10 I

Atlanta, Georgia' 30318 j

Dear Mr. Cooper:

On Mr 9,1988, % era'genics Cupuratica suhaitted a petition for rulemaking to the NRC. Se petition requested that the NRC amend 10 CFR 35.400 to add palladium-103 as a sealed source in seeds for j

l interstitial treatment of cancer.

1

%e NRC considered the petition and dete mined that there will be minimal risk j

if palladium-103 as a sealed sourm in seeds is used in aamrdanm with the manufacturer's radiation safety and handlity instructions. % erefore, the NRC published a final amcndment on Ct+% 12, 1989 in the Me.nl Reaister (54 FR 41819). A copy of the Federal Register notice is enclosed for your information.

Sincerely, Sher Bahadur, Chief Regulation Development Branch Division of Regulatory Applications Office of Nuclear Regulatory Researth

Enclosure:

FR notice i

l 9804100377 980407 l

l~

PDR FOIA THOMPSON 98-86 PDR W-

)

Nov 0 3 Iggg 7

Mr. Howard T. Cooper Regulatory and Medical Affairs Director

'Iberagenics Corporation 430 'Ibnth Street, N.W., Suite N 210 Atlanta, Georgia 30318

Dear Mr. Cooper:

On C+wier 9,1988, 'Iheragenics Corporation subnitted a petition for rulemaking to the NRC. 'Ihe petition requested that the NRC amend 10 CFR 35.400 to add nalladium-103 as a sealed source in==k for interstitial treatment of cancer.

'Ihe NRC considered the petition and determined that there will be minimal risk if palladium-103 as a sealed source in seeds is used in accordance with the manufacturer's radiation safety and handling instructions.. 'Iherefore, the NRC published _a f%1 amendment on October 12, 189 in the Feder_al Recister (54 FR 41819). A copy of the Federal Register notice is enclosed for your information.

Sincerely, S

Sher Bahadur, 011ef Regulation Development Branch Division of Regulatory Applications Office of Nuclear Regulatory Research

Enclosure:

FR notice DISTRIRTI' ION: (w/o encl.)

Subj h n-circ RDB reading SBahadur JIblford l

M.y ~ t Dalowe, NMSS l

BGolden, AIN l

LBo11ing, GPA l

OFF:-

RDB/

RDB I

NAME:

A'nq Jfe ord SBahadur DATE:

10/:0/89, 10g/89

,.20/02/89 18 L